JBIO is Jade Biosciences, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $19.90. Market cap: $1.27B.
Stock snapshot
| Price | $19.90 |
| Market cap | $1.27B |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About JBIO
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Related non-dividend companies
Other non-dividend stocks investors research alongside JBIO. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is JBIO's current stock price?
JBIO (Jade Biosciences, Inc.) is currently trading at $19.90.
Does JBIO pay a dividend?
JBIO (Jade Biosciences, Inc.) does not currently pay a regular dividend.
Track JBIO in DiviDrip
Add JBIO to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search JBIO and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-07. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.